stockrowStryker Corporation
SYK Healthcare Medical Devices
Stryker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $25.1 billion, up 11.2% from fiscal 2024.
- Revenue
- +7.64%
- EPS
- −12.4%
- Free cash flow
- −19.4%
- Total debt
- −10.0%
Quarter to September 2026, against a year earlier
Follow SYK
Alert me
Stryker Corporation (SYK) EPS (diluted)
Stryker Corporation's EPS (diluted) for fiscal 2025 was $8.40, up 8.25% from $7.76 in fiscal 2024. Over the twelve months to 30 September 2026 it was $9.39. Over the past ten years it has ranged from $2.68 (fiscal 2017) to $9.34 (fiscal 2018); the current reading is higher than 91% of that period. Stryker Corporation ranks 4th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $8.40 | 8.25% |
| FY2024 | $7.76 | (5.94%) |
| FY2023 | $8.25 | 33.71% |
| FY2022 | $6.17 | 18.43% |
| FY2021 | $5.21 | 24.05% |
| FY2020 | $4.20 | (23.36%) |
| FY2019 | $5.48 | (41.33%) |
| FY2018 | $9.34 | 248.51% |
| FY2017 | $2.68 | (38.39%) |
| FY2016 | $4.35 | 15.08% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $1.96 | (40.61%) |
| Jun 2026 | $3.30 | 70.98% |
| Mar 2026 | $1.93 | (12.27%) |
| Dec 2025 | $2.20 | (0.90%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| SYK Stryker Corporation | $9.39 |
| STE STERIS plc compare | $8.43 |
| GEHC GE HealthCare Technologies Inc. compare | $4.76 |
| MDT Medtronic PLC compare | $4.06 |
| ABT Abbott Laboratories compare | $2.68 |
| DXCM DexCom, Inc. compare | $2.55 |
| BSX Boston Scientific Corporation compare | $2.36 |
| EW Edwards Lifesciences Corporation compare | $1.77 |
| PHG Koninklijke Philips N.V. compare | $1.17 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on SYK
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement